Diet and bacteria combination limits cancer progression

 

Researchers from the University of Luxembourg have discovered a combination of dietary factors and gut bacteria that inhibits the progression of colorectal cancer. The findings, published in the open-access journal Cell Reports, could help exploit dietary regimens for therapeutic purposes to improve chemotherapy efficacy and reduce toxicity.

Link between diet and cancer progression

The diet of a person can have significant effects on the gut microbiome, i.e. the populations of microorganisms such as bacteria which live in the human gut. It is well recognised that dietary habits through complex metabolic interactions contribute to cancer prevention. More specifically, diets rich in fibre reduce the risk of developing specific cancers such as colorectal cancer (CRC). Although such diets are an effective means of cancer prevention, their possible roles in cancer progression and treatment remains poorly understood.

A team of scientists from the Luxembourg Centre for Systems Biomedicine (LCSB) and the Life Sciences Research Unit (LSRU) at the University of Luxembourg has found that a combination of prebiotics, such as dietary fibre, and probiotics, i.e. specific beneficial bacteria, reduces the expression of pro-carcinogenic and drug resistance genes. The combination leads to metabolic changes that affect the growth of cancer cells and may help treat diseases such as CRC.

Real-life interactions between dietary fibre, bacteria and human cells

In order to study diet-microbiome-host interactions, the biologists worked with HuMiX (“Human-Microbial X(cross)-talk”) a unique in vitro model of the gut (“gut-on-a-chip”) which allows the cultivation of human intestinal cells together with bacteria under representative conditions. In this study, they investigated the effects of dietary regimens and a specific probiotic on CRC cells.

In contrast to individual fibre-rich or probiotic treatments, it was only the combination of fibre and probiotics that led to the observed beneficial effects. Together with their collaborators, the researchers integrated a computer-based metabolic model of the interactions between diet, host, and microbiome. They identified the effects of the combined treatment: the downregulation of genes associated with colorectal cancer and drug-resistance as well as the attenuation of self-renewal capacity of the cancer cells. Importantly, through careful molecular analyses, they also identified the cocktail of molecules produced by the combination, thereby providing a mechanistic basis for the observed beneficial effects.

“Currently, cancer patients are not provided with evidence-based personalised dietary interventions during chemotherapy treatment. Our results provide support for exploiting the food-microbiome interactions as a supportive therapeutic approach in anti-cancer therapy,” explains Dr. Kacy Greenhalgh, post-doc within the Eco-Systems Biology group at LCSB and the lead author of the study. “I hope that our results will reach patients and medical practitioners in their respective fields and that in the future more effort is put in including personalised dietary recommendations into cancer treatment plans.”

“This is especially the case in CRC, where the microbiome has increasingly gained importance over the last couple of years. A deeper understanding of the microbiome-host interaction could lead to new therapeutic strategies for CRC patients,” adds Dr. Elisabeth Letellier, principal investigator within the Molecular Disease Mechanisms Group at LSRU.

Collaborative and interdisciplinary approach

The research project was successfully carried out thanks to the collaborative effort of different groups at the University of Luxembourg. “Deciphering the complex host-diet-microbiome interactions and their effect on health and disease states requires the concerted effort of experts from different fields. The interdisciplinary approach was crucial for understanding the very complex molecular processes underlying the observed beneficial biological effects,” comments Associate Professor Paul Wilmes, head of the Eco-Systems Biology group at LCSB and senior author of the study.

The study was supported by the Luxembourg National Research Fund (FNR), the University of Luxembourg and the Personalised Medicine Consortium (PMC).

Caption: “Some of the researchers who carried out the study. From left to right: Audrey Frachet, Serge Haan, Elisabeth Letellier, Kacy Greenhalgh, Rashi Halder, Javier Ramiro-Garcia and Paul Wilmes.” Photo: © University of Luxembourg

More highlights from this domain

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement